Cargando…
Lupus anticoagulant and mortality in patients hospitalized for COVID-19
Coronavirus disease 2019 (COVID-19) is characterized by a procoagulant state that can lead to fatal thromboembolic events. Several studies have documented a high prevalence of lupus anticoagulant that may at least partially explain the procoagulant profile of COVID-19. However, the association betwe...
Autores principales: | Gazzaruso, Carmine, Mariani, Giuseppe, Ravetto, Carolina, Malinverni, Laura, Tondelli, Elena, Cerrone, Maria, Sala, Vittorio, Bevilacqua, Luigi, Altavilla, Teodoro, Coppola, Adriana, Gallotti, Pietro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648549/ https://www.ncbi.nlm.nih.gov/pubmed/33159639 http://dx.doi.org/10.1007/s11239-020-02335-w |
Ejemplares similares
-
High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia
por: Gazzaruso, Carmine, et al.
Publicado: (2020) -
Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19
por: Gazzaruso, Carmine, et al.
Publicado: (2020) -
Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin
por: Gazzaruso, Carmine, et al.
Publicado: (2021) -
Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity
por: Gazzaruso, Carmine, et al.
Publicado: (2020) -
Evaluation of circulating sRAGE in osteoporosis according to BMI, adipokines and fracture risk: a pilot observational study
por: Galliera, Emanuela, et al.
Publicado: (2017)